Trial | NCT01052597  Report issue

Title

Curcumin for Type 2 Diabetic Patients
Antiatherogenic and Antimetabolic Effect of Curcumin in Type 2 Diabetic Patients

  • Phase

    Phase 4

  • Study Type

    Interventional

  • Status

    Unknown status

  • Intervention/Treatment

    curcumin ...

  • Study Participants

    200
There are evidence that there is an association between insulin resistance and prolonged hyperinsulinemia or hyperglycemia in Type 2 diabetic patients. This will trigger oxidative stress system via reactive oxygen species (ROS) and lead to a high level of Nitric oxide. This can contribute to a significant change in blood vessel and could end up with the complications from cardiovascular disease and increased mortality rate of type 2 diabetic patients. The purpose of the present study was to examine the effectiveness of the curcumin in type 2 diabetic patients on the reduction of atherosclerosis events by examining pulse-wave velocity (PWV) and plasma high-sensitivity C-reactive protein (CRP) test and on blood sugar lowering, glycosylated hemoglobin (HBA1c), lipid profile, and insulin resistance.
Study Started
Jul 31
2009
Primary Completion
Feb 28
2010
Anticipated
Study Completion
Mar 31
2010
Anticipated
Last Update
Jan 20
2010
Estimate

Drug curcumin

Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months

  • Other names: Manufactured by Government Pharmaceutical Organization, Thailand

Placebo Placebo Comparator

Curcumin Experimental

Criteria 

Inclusion Criteria:

Diabetic patients aged 35 years or older and did not use insulin during the first 5 years of treatment after being diagnosed (with or without symptoms listed in the following inclusion criteria)
Patient with hyperlipidemia (Cholesterol ≥ 200 mg/dl, TG ≥ 150 mg/dl, LDL ≥ 100 mg/dl and HDL ≥ 35 mg/dl)
Patient with hypertension (Blood pressure ≥ 130/85 mmHg or take hypertensive drugs)
Obesity (BMI ≥ 25)

Exclusion Criteria:

Current diagnosis of secondary peripheral arterial disease (PAD) (except listed in the inclusion criteria item 1-4)
Current diagnosis of cardiovascular disease, i.e., coronary arterial disease and cerebrovascular disease
Current diagnosis of end stage renal function with serum creatinine > 2.0 mg/dl or on renal dialysis
Current diagnosis of cirrhosis with ALT ≥ 3 times of normal range
No Results Posted